Lynparza® (olaparib) – New indication
June 1, 2023 - AstraZeneca announced the FDA approval of Lynparza (olaparib), in combination with abiraterone and prednisone or prednisolone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
Top